Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-003 in Pulmonary Arterial Hypertension (PAH)
NCT07593027Phase 2Recruiting
- Sponsor
- ImmuneCare (Suzhou) Biopharmaceuticals Co., Ltd.
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Fc-fusion protein, Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing IMC-003 with placebo of IMC-003 (2 arms). Primary endpoints: Phase Ib Primary Endpoint at 24 weeks and Phase IIa Primary Endpoint at 24 weeks. Started Apr 2026; status: recruiting.
02
Drugs
IMC-003
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT07593027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593027.